PRECLINICAL AND CLINICAL EVALUATIONS OF CEFTAZIDIME (CAZ, SN401)

DOI Web Site 1 Citations
  • KUMADA TEPPEI
    Department of Internal Medicine, Tokyo Women's Medical College
  • OOI SEISHI
    Department of Internal Medicine, Tokyo Women's Medical College
  • TOTSUKA KYOICHI
    Department of Internal Medicine, Tokyo Women's Medical College
  • TAMAKI IWAO
    Department of Internal Medicine, Josai Hospital

Bibliographic Information

Other Title
  • Ceftazidimeの基礎的・臨床的研究
  • Ceftazidime ノ キソテキ リンショウテキ ケンキュウ

Search this article

Abstract

In vitro and clinical studies on ceftazidime (CAZ, SN401) were carried out and the following results were obtained:<BR>The antibacterial activity of CAZ against E.coli (14 strains), Klebsiella (27) and Serratia (27) was compared with that of CMZ, and CAZ was found to be higher. Its activity was comparable to that of CFS against 24 strains of P.aeruginosa. The plasma concentration and the urinary recovery of CAZ were determined by 1-IPLC. The mean plasma concentration immediate after an i. v. dose of 1g was 138 μg/ml, and at 30 minites, it reached 62 μg/ml. The plasma halflife was 1.6-1.8 hours. The urinary recovery averaged 93% of the dose in the first 6 hours after injection.<BR>As to the clinical response, CAZ was given to 9 patients with complicated urinary tract infections, and the results were assessed as good in 8 and fair in 1.<BR>When CAZ was evaluated microbiologically, E.coli, Serratia, Proteus and Enterobacter were eradicated but no change was observed as to S. faecalis. From the above, CAZ was considered to have broad antibacterial spectrum against gram-negative bacilli including P.aeruginosa and to be highly useful in the clinical use.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 31 (Supplement3), 258-262, 1983

    Japanese Society of Chemotherapy

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top